LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Inicio・Lista de Acciones・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Cerrado

SectorSanidad

90.65 4.1

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

86.93

Máximo

91.45

Métricas clave
By Trading Economics
Ingresos	-8.1M -56M
Ventas	2.9M 60M
BPA	-0.83
Margen de beneficios	-92.559
Empleados	414
EBITDA	-9.7M -52M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+45.24% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	124M 6B
Apertura anterior	86.55
Cierre anterior	90.65

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

60 / 65.58 Soporte y Resistencia

Rhythm Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 may 2026, 22:50 UTC

Ganancias

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 may 2026, 22:49 UTC

Ganancias

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 may 2026, 22:32 UTC

Ganancias

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 may 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 may 2026, 22:57 UTC

Charlas de Mercado

Ganancias

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 may 2026, 22:26 UTC

Ganancias

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 may 2026, 22:25 UTC

Ganancias

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 may 2026, 22:25 UTC

Ganancias

Aristocrat Leisure Interim Dividend A$0.50/Security

12 may 2026, 22:24 UTC

Ganancias

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 may 2026, 22:23 UTC

Ganancias

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 may 2026, 22:23 UTC

Ganancias

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 may 2026, 22:19 UTC

Ganancias

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 may 2026, 22:14 UTC

Ganancias

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 may 2026, 22:14 UTC

Ganancias

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 may 2026, 22:13 UTC

Ganancias

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 may 2026, 22:12 UTC

Ganancias

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 may 2026, 22:12 UTC

Ganancias

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 may 2026, 22:11 UTC

Ganancias

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 may 2026, 22:11 UTC

Ganancias

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 may 2026, 22:10 UTC

Ganancias

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 may 2026, 22:09 UTC

Ganancias

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 may 2026, 22:09 UTC

Ganancias

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 may 2026, 22:08 UTC

Ganancias

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 may 2026, 22:07 UTC

Ganancias

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 may 2026, 22:06 UTC

Ganancias

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 may 2026, 22:06 UTC

Ganancias

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 may 2026, 22:05 UTC

Ganancias

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 may 2026, 22:04 UTC

Ganancias

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 may 2026, 22:04 UTC

Ganancias

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 may 2026, 22:04 UTC

Ganancias

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Comparación entre iguales

Cambio de precio

Rhythm Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

45.24% repunte

Estimación a 12 Meses

Media 136.77 USD 45.24%

Máximo 158 USD

Mínimo 105 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

Comprar

Mantener

Vender

De acuerdo con 14 analistas que ofrecen calificaciones bursátiles a para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

60 / 65.58Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.